Candice Clark
Family · Houston, TXNPI 1760932537
Payments from drug & device makers
Across 98 payments — averaging $24.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$478
- Astellas Pharma US Inc$374
- Endo Pharmaceuticals Inc.$288
- Sumitomo Pharma America, Inc.$275
- Endo USA, Inc.$181
- Pfizer$89
- plus $694 from 16 others
What the payments were for
- Food & beverage$2,20893%
- Education$1737%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 12 | $478 |
| Astellas Pharma US Inc | 13 | $374 |
| Endo Pharmaceuticals Inc. | 16 | $288 |
| Sumitomo Pharma America, Inc. | 15 | $275 |
| Endo USA, Inc. | 9 | $181 |
| Pfizer | 4 | $89 |
| Ferring Pharmaceuticals Inc. | 3 | $71 |
| Johnson & Johnson | 1 | $69 |
| Convatec Inc. | 2 | $69 |
| Urovant Sciences Inc | 3 | $62 |
| Myriad Genetic Laboratories, Inc. | 2 | $61 |
| AbbVie(2 entities) | 3 | $58 |
| Antares Pharma, Inc. | 3 | $49 |
| Bayer | 2 | $48 |
| Halozyme Inc | 2 | $38 |
| KARL Storz Endoscopy-america | 1 | $37 |
| Boston Scientific | 2 | $31 |
| 180 Medical, Inc. | 1 | $25 |
| Sanofi | 1 | $23 |
| Myovant Sciences Inc. | 1 | $19 |
| Clarus Therapeutics Inc. | 1 | $17 |
| Hollister Incorporated | 1 | $16 |
How this compares
$2,381 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 23 | $26,087 |
| MyrbetriqMirabegron | 18 | $14,070 |
| Mirabegron ErMirabegron | 12 | $5,384 |
| Tamsulosin Hcl | 165 | $3,102 |
| Testosterone Cypionate | 48 | $2,187 |
| Dutasteride | 27 | $2,057 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 120 | $2,054 |
| Cephalexin | 95 | $1,526 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 133 | $1,397 |
| Oxybutynin Chloride ErOxybutynin Chloride | 45 | $1,322 |
| Solifenacin Succinate | 17 | $753 |
| Estradiol | 24 | $737 |
| Anastrozole | 183 | $735 |
| NitrofurantoinNitrofurantoin Macrocrystal | 13 | $505 |
| Ciprofloxacin Hcl | 96 | $469 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $275 | $26,08723 claims |
| Astellas Pharma US IncMyrbetriq | $374 | $14,07018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.
Other family in Houston
- Lashonda CraneHouston$3.4M
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Margaret WhiteHouston$85K
- Cheryl HaseebHouston$42K
- David WeirDallas$959K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.